Replace Therapeutics

Acquired By Tome Biosciences
CRISPR-based genome editing platform is developed for genetic diseases.
Request Access
Report Incorrect Data
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Replace Therapeutics

A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.

  • Sectors
    Healthcare
  • Phone
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies → Unlock Sub-Sector → Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Tome Biosciences
  • Employee Count
    Not available
  • Acquired by
    Tome Biosciences

    (Jan 02, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Replace Therapeutics

Premium access

Detailed funding history for Replace Therapeutics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Replace Therapeutics

Replace Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Tome Biosciences.

All
Investor Description Founded Year Domain Location
Tome Biosciences
CRISPR-based gene insertion platform for genomic medicines is developed.
Locked Locked Locked
Premium access

Investor details for Replace Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Replace Therapeutics

Investments
Premium access

Investment portfolio details for Replace Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Replace Therapeutics

Premium access

Detailed financials for Replace Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Replace Therapeutics Comparisons

Replace Therapeutics Primary company
Description
CRISPR-based genome editing platform is developed for geneti...
Location
-
Founded Year
-
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Replace Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Replace Therapeutics

Premium access

Detailed competitors of Replace Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Replace Therapeutics

Premium access

Complete news archive for Replace Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Replace Therapeutics

Shakked Halperin is the current CEO of Replace Therapeutics.

A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.

Replace Therapeutics has 1 investor. Key investors include Tome Biosciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available